Ardelyx (ARDX) Total Liabilities (2013 - 2026)
Ardelyx's (ARDX) quarterly Total Liabilities came in at $355.9 million in Q1 2026, up 34.54% YoY from $264.5 million in Q1 2025, and up 6.34% on a QoQ basis from $334.7 million in Q4 2025.
Ardelyx (ARDX) Total Liabilities (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Total Liabilities data on file, last reported at $355.9 million in Q1 2026.
- Quarterly Total Liabilities rose 34.54% year-over-year to $355.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $355.9 million (up 34.54% YoY) and the FY2025 annual result came in at $334.7 million, up 27.5% from the prior year.
- Total Liabilities improved to $355.9 million in Q1 2026, from $334.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $355.9 million in Q1 2026 to a low of $65.2 million in Q1 2022.
- A 5-year average of $188.0 million and a median of $191.5 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities retreated 17.95% — and 2024, when it soared 123.19%.
- Tracing ARDX's Total Liabilities over 5 years: stood at $91.7 million in 2022, then soared by 42.54% to $130.8 million in 2023, then soared by 100.72% to $262.5 million in 2024, then gained by 27.5% to $334.7 million in 2025, then increased by 6.34% to $355.9 million in 2026.
- The last three Total Liabilities figures came in at $355.9 million (Q1 2026), $334.7 million (Q4 2025), and $331.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 426.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 426.88 Mn |
| Mar 31, 2026 | 355.89 Mn |
| Dec 31, 2025 | 334.66 Mn |
| Sep 30, 2025 | 331.89 Mn |
| Jun 30, 2025 | 327.24 Mn |
| Mar 31, 2025 | 264.52 Mn |
| Dec 31, 2024 | 262.47 Mn |
| Sep 30, 2024 | 209.57 Mn |
| Jun 30, 2024 | 196.50 Mn |
| Mar 31, 2024 | 191.49 Mn |
| Dec 31, 2023 | 130.76 Mn |
| Sep 30, 2023 | 98.22 Mn |
| Jun 30, 2023 | 88.04 Mn |
| Mar 31, 2023 | 91.60 Mn |
| Dec 31, 2022 | 91.74 Mn |
| Sep 30, 2022 | 77.81 Mn |
| Jun 30, 2022 | 78.57 Mn |
| Mar 31, 2022 | 65.22 Mn |
| Dec 31, 2021 | 67.30 Mn |
| Sep 30, 2021 | 89.42 Mn |